Letter to the editor: Immunomodulation by phsphodiesterase-4 inhibitor in COVID-19 patients

we read with interest the commentary by Dalamaga and colleagues [1] that brought to the attention of the scientific community the potential role of Phosphodiesterase 4 (PDE4) inhibitors in the treatment of SARS-CoV-2 infection. Coronavirus disease 2019 (COVID-19) is associated with a variable clinical picture, ranging from mild “flu-like” cases to severe interstitial pneumonia leading to fatal respiratory insufficiency. This heterogeneity is attributed to the degree of the host’s inflammatory reaction and cytokine production [2].
Source: Metabolism - Clinical and Experimental - Category: Biomedical Science Authors: Source Type: research